BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 14, Issue 3
  • This Article
Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Journal Information of This Article
Publication Name
World Journal of Virology
ISSN
2220-3249
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews
©The Author(s) 2025.
World J Virol. Sep 25, 2025; 14(3): 108754
Published online Sep 25, 2025. doi: 10.5501/wjv.v14.i3.108754
Figure 3
Full Size Figure Download Figure
Figure 3 Future research directions in hepatitis C virus-related cardiomyopathy. Research priorities include elucidating pathogenic mechanisms to enable the development of targeted therapies, validating early-detection biomarkers (e.g., Mac-2 binding protein glycan isomer, Angiopoietin-2), and ultimately improving global access to direct-acting antiviral agents. These strategies align with the World Health Organization’s goal of eliminating viral hepatitis as a public health threat by 2030. Ang2: Angiopoietin-2; DDA: Direct-acting antiviral agent; M2BPGi: Mac-2 binding protein glycan isomer; WHO: World Health Organization.
Write to the Help Desk
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.